Logo

Pfizer Reports Results of PF-06410293 (biosimilar, adalimumab) in the Sub-Study for the Treatment of Rheumatoid Arthritis

Share this
Pfizer Reports Results of PF-06410293 (biosimilar, adalimumab) in the Sub-Study for the Treatment of Rheumatoid Arthritis

Pfizer Reports Results of PF-06410293 (biosimilar, adalimumab) in the Sub-Study for the Treatment of Rheumatoid Arthritis

Shots:

  • The sub-study of a P-III trial of PF-06410293 which was available for inj. in PFS & PEP vs EU Humira given via PFS in a ratio (1:1) in 49 patients with RA. The study evaluated the usability of PFP
  • Following the administration of ~294 inj., DSSR (100%), no additional safety assessments were conducted for the PFP sub-study, AEs were consistent with those reported in the overall study, no medical device complaints, 95.9% of patients who completed the sub-study elected to continue study treatment using PFP inj.
  • The patients have received 2 biosimilar doses through PFS @52 & 54wks. and then 6 additional biweekly doses via PFP device. In previous studies, Humira autoinjector pens are suitable & easy to use

Ref: The Center For Biosoimilars | Image: Pfizer

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions